Dexter, Distalmotion’s surgical robot has already completed over 1000 surgeries in Europe. The company has now completed a new financing round led by Revival Healthcare with participation from the Swiss Entrepreneurs Fund to fuel the company’s commercial phase.
Distalmotion’s flagship product, Dexter, is a compact surgical robot designed to enhance laparoscopic procedures with robotic precision. The company has developed an optimal combination of technique, tools and technology, whilst maintaining access to the patient, which gives surgeons the ultimate control of patient treatment. Featuring two articulated arms and an intuitive console, Dexter allows surgeons to seamlessly switch between robotic and traditional techniques to perform operations based on their preferences. Its compatibility with existing laparoscopic systems makes it a versatile tool for minimally invasive surgeries across various specialities.
Dexter is currently being used in clinical environments in Europe, successfully treating patients across a multitude of complex and high-volume procedures in general surgery, gynaecology and urology, demonstrating its versatility, safety, and efficacy in treating patients. Since its first installation in 2022, the CE-Mark certified, the device surpassed 1000 procedures, underscoring the device’s maturity and reliability. Hospitals such as Saintes in France have even integrated Dexter into their robotic surgery programs.
With the submission of the FDA approval in the US, Distalmotion is moving from an engineering-driven company to a commercially driven company. Early this year, the company partnered with Proximie, the leading global health technology platform digitizing operating rooms (ORs), to extend its ground-breaking Dexter robotic surgery platform globally. Distalmotion customers will get access to Proximie's healthcare platform, offering telepresence, content management, and data driven insights. With Proximie, surgeon expertise and OR data can be easily shared from anywhere, generating new insights to help improve patient outcomes and productivity. With the combination of Distalmotion’s Dexter and Proximie systems, this partnership enables the seamless exchange of knowledge and learnings and information among surgeons, fostering greater collaboration to deliver the highest quality surgical care.
The proceeds from its recent funding round will allow the company to support this next growth phase. In addition to the investment from led investor Revival Healthcare, the Swiss Entrepreneurs Fund (SEF) also made a direct investment in the EPFL spinoff, securing a minority stake in the company. Helvetica Capital advised the SEF in this transaction.
(RAN)
Image: Distalmotion
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines